Fri.Nov 25, 2022

article thumbnail

AI will continue to attract investment in near future in the healthcare industry

Pharmaceutical Technology

Artificial intelligence (AI) was seen as one of the top current investment priorities and was thought to continue to attract investment in the healthcare sector in the upcoming two years, according to GlobalData's latest report ‘Digital Transformation and Emerging Technology in the Healthcare Industry - 2022 Edition’. In this survey-based report tracker, digital media was prioritised as a top current investment target, with 53% of surveyed respondents confirming that their companies are currentl

article thumbnail

Taking the right forecasting approach for rare diseases

pharmaphorum

There are approximately 7,000 different types of rare disease and researchers estimate that there are more than 300 million people worldwide living with such a condition, according to the National Institutes of Health (NIH). However, only 5% of rare diseases are estimated to have at least one approved treatment, known as “orphan” therapies. A rare disease is any disease that affects a small percentage of the population.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Kidney Damage From Diabetes Worsens Over Time

Pharmacy Times

Pharmacists play a significant role in the comprehensive management of this condition through education, intervention, and monitoring.

132
132
article thumbnail

Ozempic compensating for Wegovy’s supply shortage due to high demand

Pharmaceutical Technology

In recent months, Wegovy (semaglutide), indicated for obesity, has been subjected to widespread supply shortages due to high demand, in addition to manufacturer production problems, with Novo Nordisk intending to relaunch Wegovy by the end of 2022. In the meantime, however, Novo Nordisk’s Ozempic, another version of semaglutide indicated particularly for patients with type 2 diabetes, has picked up the slack by being used off-label for obesity patients.

Labelling 111
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

mRNA can deliver universal flu vaccine, say US researchers

pharmaphorum

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. While the shot is still in preclinical development, if it works in human trials it could raise the prospect of eventually sidestepping the annual scramble to guess the most likely strains to be circulating in the following flu season, and protect against future flu pandemics.

Vaccines 105
article thumbnail

Japan’s MHLW approves Daiichi Sankyo’s breast cancer treatment

Pharmaceutical Technology

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) to treat HER2-positive unresectable or recurrent breast cancer in adults. The treatment is indicated for usage in such patients following previous chemotherapy, comprising trastuzumab and a taxane. The latest development was based on the findings from the international, head-to-head, open-label, randomised Phase III DESTINY-Breast03 trial which analysed the efficacy a

More Trending

article thumbnail

FDA rejects Spectrum’s lung cancer drug poziotinib

pharmaphorum

The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea’s Hanmi Pharma, which originally developed the drug. Hanmi reported the FDA’s rejection of the marketing application first, as the CRL emerged during the Thanksgiving holiday in the US and the Korean company wanted to eliminate “unnecessary misunderstandings” about the timing of the disclosure given the time diff

FDA 98
article thumbnail

XtalPi and CK Life Sciences to develop AI-driven tumour vaccine R&D platform

Pharmaceutical Technology

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform. Such a platform will aid in boosting tumour vaccine discovery and design expertise as well as expedite the development of other kinds of vaccines.

article thumbnail

Health Innovators – Paolo Borella

pharmaphorum

In our final interview from Frontiers Health 2022, pharmaphorum Editor in Chief Jonah Comstock sits down with Paolo Borella, who runs the new VITA digital health accelerator in Italy. Paolo explains how the accelerator works, what the start-ups get, and how it benefits the various partners involved. Jonah and Paolo also talk a bit about what makes an accelerator work and why industry connections are such an important part of the accelerator equation.

98
article thumbnail

Improve Pain Management With Precision Pharmacotherapy

Pharmacy Times

Leveraging pharmacogenomic testing, simultaneous multidrug analysis can help prevent drug interactions affecting pain management.

139
139
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Touring Chiesi’s vision for the future at the new Biotech Centre of Excellence

pharmaphorum

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – that is the Chiesi Group’s new Biotech Centre of Excellence, you would be forgiven for thinking this was just another laboratory and/or pharmaceutical manufacturing plant; because it quite simply isn’t.

FDA 98
article thumbnail

Q&A: Siddhartha Mukherjee on the rapid pace of cancer research and ‘luminous’ life of cells

STAT

The first cells Siddhartha Mukherjee ever saw were T cells, pulled from a mouse spleen and plated onto the microscope slide, given chemicals to coax them to grow. When he looked down the scope, he was struck by the life in them, marveling at what he called their “inner glow and luminous fullness.” That thrill Mukherjee feels each time he sees life under the microscope carries into his new book, “The Song of the Cell.

91
article thumbnail

EU launches AI-powered real-world data project for cancer therapies

pharmaphorum

The European Commission has provided around €7 million ($7.2 million) in funding to a new project that aims to boost the ability of hospitals within the EU to collect real-world data (RWD) to gauge the effectiveness of novel cancer therapies. Dubbed ONCOVALUE, the initiative will set up a consortium that will develop an artificial intelligence (AI) platform that will be used for routine collection and analysis of clinical data on new oncology medicines to support their assessment by regulators a

article thumbnail

First patient dosed with novel RNA modifying enzyme inhibitor

European Pharmaceutical Review

STC-15, a first-in-class ribonucleic acid (RNA) modifying enzyme inhibitor, has been dosed in the first patient in a clinical trial, making it the first molecule targeting an RNA methyltransferase to enter clinical development. Storm Therapeutics oral METTL3 inhibitor is being assessed in the Phase I study ( NCT05584111 ) to examine the drug’s effect on solid tumours.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Best of Health Systems Coverage in 2022

Drug Topics

Take a look back at our most popular health system coverage for 2022.

112
112
article thumbnail

NICE recommends new life-extending treatment for rare form of gastroesophageal cancer

Pharmafile

Clinical evidence shows Bristol Myers Squibb’s nivolumab, with chemotherapy, could help extend the lives of patients with untreated HER2-negative, advanced or metastatic gastric, gastroesophageal junction, or oesophageal adenocarcinoma, if the tumours express PD-L1. HER2-negative cancer cells tend to grow more slowly and are less likely to spread. read more.

article thumbnail

News Roundup: November 21 to November 25

Drug Topics

Your weekly roundup of the latest news from Drug Topics®.

98
article thumbnail

NHS nurses strike announced for 15 and 20 December

Pharmafile

The Royal College of Nursing (RCN) has announced strikes on 15 and 20 December in a continuing pay dispute with the government. The RCN says it has been given no choice after ministers blocked further talks about a pay rise. Emergency care will still be provided, however. Under trade union laws, the RCN has to ensure life-saving care is provided during the strikes, meaning some urgent care services, urgent tests and scans, and ongoing care for vulnerable patients will be protected, alongside A&a

article thumbnail

21 CFR PART 11 - Guidance for Industry

Pharma Tutor

21 CFR PART 11 - Guidance for Industry. admin. Sat, 11/26/2022 - 12:48. This guidance is intended to describe the FDA's current thinking regarding the scope and application of part 11 of Title 21 of the Code of Federal Regulations (CFR); Electronic Records; Electronic Signatures and is in effect since August 20 1997.

FDA 52
article thumbnail

Canadian HCPs given digital era empowerment recommendations

pharmaphorum

The latest market study report from the Competition Bureau has provided recommendations to health care providers (HCPs) on how to improve the ways they work within Canada’s public health system. ‘Empowering health care providers in the digital era’ is the Competition Bureau’s third and final report published as part of its digital health care market study , which examines how pro-competitive policies can foster innovation and bring about greater choice and access to digital health care services

52
article thumbnail

Who’s hiring who? Hiring activity related to environmental sustainability decreased by 2% in the pharmaceutical industry in Q3 2022

Pharmaceutical Technology

The global pharmaceutical industry experienced a 2% drop in new job postings related to environmental sustainability in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This compares to a 2% increase in the previous quarter and a 22% increase versus Q3 2021. Notably, Building Cleaning Workers jobs accounted for a 9% share of the global pharmaceutical industry’s environmental sustainability-related total new job postings in Q3 2022, up 1% over the

article thumbnail

Grünenthal buys into Kyowa Kirin’s mature medicines portfolio

pharmaphorum

German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan’s Kyowa Kirin, which are currently sold by affiliate companies across Europe. The first stage of the rights transfer is the formation of a joint venture between the two companies – 51% owned by Grünenthal – that will have rights to the brands, which have annual revenues of around €200 million ($207 million) a year.

52
article thumbnail

Who’s hiring who? Hiring activity related to cybersecurity increased by 30% in the pharmaceutical industry in Q3 2022

Pharmaceutical Technology

The global pharmaceutical industry experienced a 30% rise in new job postings related to cybersecurity in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This compares to a 30% increase in the previous quarter and a 70% increase versus Q3 2021. Notably, Registered Nurses jobs accounted for a 9% share of the global pharmaceutical industry’s cybersecurity-related total new job postings in Q3 2022, up 1315% over the prior quarter.

40
article thumbnail

Episode 526: PREMIUM – The latest on salt and vitamins

Therapeutics Education Collaboration

In episode 526, Mike and James go PREMIUM yet again, although it takes a while – so stay till the end. We go over the latest research on low sodium in heart failure, Vitamin D for preventing COVID, and multivitamins for doing anything. Show Notes 1) Reduction of dietary sodium to less than 100 mmol… This content is for members only. Visit the site and log in/register to read.

52
article thumbnail

Who’s hiring who? Hiring activity related to cloud decreased by 8% in the pharmaceutical industry in Q3 2022

Pharmaceutical Technology

The global pharmaceutical industry experienced an 8% drop in new job postings related to cloud in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This compares to an 8% increase in the previous quarter and a 21% increase versus Q3 2021. Notably, Software and Web Developers, Programmers, and Testers jobs accounted for a 19% share of the global pharmaceutical industry’s cloud -related total new job postings in Q3 2022, down 17% over the prior quart

40
article thumbnail

November Case Studies- Cough

Pharmacy Times

This issue's OTC Cases answer common questions about a cough.

65
article thumbnail

Who’s hiring who? Hiring activity related to artificial intelligence increased by 7% in the pharmaceutical industry in Q3 2022

Pharmaceutical Technology

The global pharmaceutical industry experienced a 7% drop in new job postings related to artificial intelligence in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This compares to a 7% increase in the previous quarter and a 63% increase versus Q3 2021. Notably, General and Operations Managers jobs accounted for an 11% share of the global pharmaceutical industry’s artificial intelligence-related total new job postings in Q3 2022, up 12% over the p

40
article thumbnail

Depressive therapy Spravato demonstrates superior efficacy

Pharma Times

Research supports use of Spravato nasal spray in adults with major depressive disorder

51
article thumbnail

The Fundamental Gut Health Protocol

The Thyroid Pharmacist

Bloating, stomach pain, irritable bowel syndrome (IBS), and acid reflux were a part of my long list of symptoms that I experienced for almost a decade before my Hashimoto’s diagnosis. We often view digestive symptoms as annoying and uncomfortable (I definitely did!), but they’re also very important clues to what’s going on with our health. Once I began to discover the connection between the gut and Hashimoto’s, I realized that I had an important key in my hands to help me unlock my own remission

article thumbnail

Bristol Myers Squibb immunotherapy-chemo combination gets NICE recommendation

Pharma Times

Treatment involves adults with certain forms of advanced stomach and oesophageal cancer

48
article thumbnail

Automated cell biology systems market to reach $33.5 billion by 2032

European Pharmaceutical Review

According to Future Market Insights’ most recent report , the global automated cell biology systems market stands at $14.1 billion in 2022 and is anticipated to be worth around $33.5 billion in 2032, due to rising demand for personalised medicine and increased total lab automation techniques. The research showed lab automation, made possible by new technologies and applications, have become a major focus in the biotechnology sector over the last two decades.

87
article thumbnail

Rising demand for pediatric dosage forms requires reformulation, expertise, and to-scale manufacturing capabilities

Pharmaceutical Technology

Pharmaceutical companies are looking to paediatric indications of approved adult dosage forms (ADFs) to sustain and fuel growth. The desire to develop paediatric dosage forms (PDFs) of drugs with existing adult indications has two main drivers: the US Food and Drug Administration’s (FDA’s) role in limiting off-label use in pediatric patients, which aligns with the FDA’s role in ensuring the safety and efficacy of approved products for all patients; and sustaining revenue growth through paediatr

Dosage 52
article thumbnail

Reinventing the drum: How milling innovations are cutting costs and reducing footprints

Pharmaceutical Technology

All evidence indicated that containment in facilities is in high demand and will be increasingly so in the future as the oncology pipeline and the use of cytotoxic drugs continues to grow. For pharmaceutical manufacturers and contract manufacturing organizations (CMOs) with containment capabilities, this likely means a distinct advantage over those without.